RxDoctor Payments DataLook up a doctor →

Janet McGill, MD

Endocrinology, Diabetes & Metabolism · Saint Louis, MONPI 1811915325

Payments from drug & device makers

$827,656in general payments, 2019–2025

Across 574 payments — averaging $1441.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$463K
  • Dexcom, Inc.$66K
  • Mannkind Corporation$42K
  • Novo Nordisk AS$36K
  • Lexicon Pharmaceuticals, Inc.$35K
  • Novo Nordisk$29K
  • plus $155K from 30 others
$26,565in research payments, 2019–2025

Across 25 payments — averaging $1062.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bayer$23K
  • Lexicon Pharmaceuticals, Inc.$2K
  • Novo Nordisk AS$1K
  • Gilead$1K

What the payments were for

  • Consulting fees$91,27643%
  • Speaking & faculty fees$62,62730%
  • Travel & lodging$43,66621%
  • Food & beverage$14,4627%
  • Education$340%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$827,656 in reported general payments places this provider in the 95th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.

See all endocrinology, diabetes & metabolism providers in Missouri

Medicare billing

Part B allowed, 2024
$45,119
Medicare patients
190
Services billed
676

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide141$177,352
OzempicSemaglutide104$159,970
MounjaroTirzepatide133$153,176
JardianceEmpagliflozin78$101,775
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/755$65,886
FarxigaDapagliflozin Propanediol43$38,516
NovologInsulin Aspart47$20,930
Humalog Kwikpen U-200Insulin Lispro11$19,101
Tresiba Flextouch U-100Insulin Degludec28$19,091
Lantus SolostarInsulin Glargine,hum.Rec.Anlog125$17,694
KerendiaFinerenone16$15,878
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog31$14,012
Humalog Kwikpen U-100Insulin Lispro53$13,016
HumalogInsulin Lispro44$12,705
Novolog FlexpenInsulin Aspart47$11,893

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro$13,996$344,949336 claims
Novo NordiskOzempic, Novolog$29,410$180,899151 claims
Boehringer IngelheimJardiance$13,997$101,77578 claims
AstraZenecaFarxiga$336$38,51643 claims
BayerKerendia$18,639$15,87816 claims
Johnson & JohnsonInvokana$5,948$11,24414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.

Other endocrinology, diabetes & metabolism in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →